WALTHAM, Mass., May 16, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Earl M. (Duke) Collier, Jr. has been elected to the TESARO Board of Directors.
"On behalf of the Company and the entire board, I would like to thank Paul Walker for his leadership and years of service to TESARO. We wish him much success in his future endeavors," said Lonnie Moulder, CEO of TESARO. "I'd also like to take this opportunity to welcome our new board member, Duke Collier, who will serve as an independent director. His significant leadership experience in the biopharmaceutical industry will be a valuable asset to the Company."
Since 2010, Mr. Collier has served as chief executive officer of 480 Biomedical and executive chair of Arsenal Medical, Inc., both of which are polymer biotherapeutics companies focused on serious clinical problems unable to be solved by current therapies. Mr. Collier was president at deCODE genetics, Inc., a biopharmaceutical company, from 2009 to 2010, and was executive vice president at Genzyme Corporation from 1997 to 2009. He also has served as president of Vitas Healthcare, a partner at the law firm of Hogan & Hartson LLP, and deputy administrator of the Health Care Finance Administration (now Centers for Medicare & Medicaid Services) in the U.S. Department of Health & Human Services. Mr. Collier serves on the board of directors of 480 Biomedical, Arsenal Medical, Inc., Capricor, and TransMedics, Inc. He is also chairman of the board of trustees of Newton-Wellesley Hospital and chair of the Innovation Advisory Board of Partners Healthcare System. Mr. Collier received a bachelor of arts degree from Yale University and a law degree from the University of Virginia Law School.
TESARO also announced the results of its Annual Stockholder Meeting, which was held today at 8:30 AM Eastern Time in Waltham, Massachusetts. In addition to electing Mr. Collier, stockholders elected the other nominated directors to serve an annual term and ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.
CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or email@example.com